• Explore /
  • Poster
  • / Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).

Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).

Abstract Poster

Authors

null

Samuel Aaron Goldlust

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

Samuel Aaron Goldlust , Jong Hee Chang , Yoshitaka Narita , Mary Roberta Welch , Richard M. Green , Jan Drappatz , David Eric Piccioni , Yu Jung Kim , Jason M. Melear , Shota Tanaka , Kuo-Chen Wei , Karen L. Fink , Marshall W. Pitz , Timothy Francis Cloughesy , John Frederick de Groot , Nanci McClellan , Matthew Hitron , Bo Xu , Bo Jin , Claudia Lebedinsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Primary CNS Tumors–Glioma

Clinical Trial Registration Number

NCT03149003

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2022)

DOI

10.1200/JCO.2023.41.16_suppl.2022

Abstract #

2022

Poster Bd #

379

Abstract Disclosures

Similar Posters

First Author: Benjamin M. Ellingson

First Author: Masamichi Takahashi

First Author: Manmeet Singh Ahluwalia

First Author: Jian Li Campian